Analyst Byeongyong Oh

[ImmuneOncia] A Standout Pick Post Biotech Selloff

Rating: N.R

Target Price : -

Current Price(06/26): 3,190원

Upside : -

- Immunoncia: Yuhan's Immuno-Oncology Subsidiary

- IMC-002 Continues to Generate Consistent Data in HCC and TNBC

- The Next Major Catalyst for IMC-002 Is the BTC Clinical Readout

Report Link: http://buly.kr/C0CAfrV

Hanyang Securities Pharmaceutical/Bio Channel: https://t.me/bdragon0808

* Compliance Approval obtained